BACKGROUND: Treatments that delay progression of cognitive impairment in older adults are of great public health significance. This manuscript outlines the protocol, recruitment, baseline characteristics, and retention for a randomized controlled trial of cognitive and aerobic physical training to improve cognition in individuals with subjective cognitive dysfunction, the "Cognitive and Aerobic Resilience for the Brain" (CARB) study. METHODS: Community-dwelling, older adults with self-reported memory loss were randomly assigned to receive either computer-based cognitive training, aerobic physical training, combined cognitive and physical training, or education control. Treatment was delivered 2- to 3-times per week in 45- to 90-min sessions for 12Â weeks by trained facilitators videoconferencing into subject's home. Outcome assessments of were taken at the baseline, immediately following training, and 3-months after training. RESULTS: 191 subjects were randomized into the trial (mean age, 75.5Â years; 68% female; 20% non-white; mean education, 15.1Â years; 30% with 1+ APOE e4 allele). The sample was generally obese, hypertensive, and many were diabetic, while cognition, self-reported mood, and activities of daily living were in the normal range. There was excellent retention throughout the trial. Interventions were completed at high rates, participants found the treatments acceptable and enjoyable, and outcome assessments were completed at high rates. CONCLUSIONS: This study was designed to determine the feasibility of recruiting, intervening, and documenting response to treatment in a population at risk for progressive cognitive decline. Older adults with self-reported memory loss were enrolled in high numbers and were well engaged with the intervention and outcome assessments.
Design and baseline characteristics of the Cognitive and Aerobic Resilience for the Brain (CARB) study.
认知和有氧运动对大脑的适应性(CARB)研究的设计和基线特征
阅读:12
作者:Tam Joyce W, Khurshid Kiran, Sprague Briana, Clark Daniel O, Xu Huiping, Moser Lyndsi R, Miller Douglas K, Considine Robert, Callahan Christopher M, Garringer Holly J, Rexroth Daniel, Unverzagt Frederick W
| 期刊: | Contemporary Clinical Trials | 影响因子: | 1.900 |
| 时间: | 2023 | 起止号: | 2023 Aug;131:107249 |
| doi: | 10.1016/j.cct.2023.107249 | 研究方向: | 其它 |
特别声明
1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。
4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。
